Potential Change in Guidelines for Ticagrelor Therapy

The results of the PEGASUS-TIMI 54 trial could potentially lead to a change in clinical guidelines to extend the currently recommended 12 months of ticagrelor therapy.

This change would be contingent on patients’ ability to tolerate ticagrelor therapy beyond 12 months and through 33 months, which was the average follow-up in the PEGASUS-TIMI 54 trial.

Comparing the PEGASUS-TIMI 54 trial with the DAPT study, Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, a clinical specialist of cardiovascular medicine at Saint Barnabas Medical Center, notes the population in the former study included a more real-to-life population of higher-risk patients.